TREATMENT AND PROPHYLAXIS OF AMYLOIDOSIS
Methods useful for effecting prophylaxis or treatment of amyloidosis, including AA Amyloidosis and AL amyloidosis, by administering peptides comprising neoepitopes, such as AA fragments from a C-terminal region of AA, and antibodies specific for neoepitopes of aggregated amyloid proteins, for example, antibodies specific for the C-terminal region of AA fibrils. Antibodies for inhibition of formation and/or increasing clearance of amyloid deposits in a patient thus effecting prophylaxis or treating amyloid disease.
1 - 90 . (canceled)
91 . An isolated antibody, or antigen-binding fragment thereof, which specifically binds to an epitope comprising AEDS (SEQ ID NO: 13) in an aggregated amyloid protein.
92 . The antibody or antigen-binding fragment of claim 91 , which specifically binds to an aggregated amyloid protein at an epitope comprising an amino acid sequence GHGAEDS (SEQ ID NO:4).
93 . The antibody or antigen-binding fragment of claim 91 , wherein the antibody binds to the amyloid protein in monomeric form with an affinity of less than about 10 7 M −1 .
94 . The antibody or antigen-binding fragment of claim 91 , wherein the amyloid protein is serum amyloid A protein (SAA).
95 . The antibody or antigen-binding fragment of claim 91 , wherein the amyloid protein is selected from the group consisting of immunoglobulin light chain protein, human islet amyloid precursor polypeptide (IAPP), transthyretin (TTR) and ApoA1.
96 . The antibody or antigen-binding fragment of claim 91 , which is a human, humanized, or chimeric antibody or antigen-binding fragment.
97 . The antibody or antigen-binding fragment of claim 96 , which specifically binds to an epitope within residues 70-76 of human amyloid A peptide.